The Patent Finder

Adam6 Mice

Regeneron Pharmaceuticals, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 11 of these applications claim priority to application 61/595,200, filed Feb 6, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresPatent lifetimeUsedRemainingConfidence
US 8,642,835Adam6 Mice
In force
 · High confidence
UsedRemaining
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 8,697,940ADAM6 Mice
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 9,932,408ADAM6 Mice
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 9,944,716ADAM6 Mice
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 10,072,095ADAM6 Mice
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 10,577,430ADAM6 Mice
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 10,694,725ADAM6 Mice
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
US 11,950,578ADAM6 Mice
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 12,207,628ADAM6 Mice
In force
 · Medium confidence
Regeneron Pharmaceuticals, Inc.In forceMedium confidence
US 10,905,108ADAM6 Mice
In force
 · High confidence
Regeneron Pharmaceuticals, Inc.In forceHigh confidence
2 more records in this group · Pro
10 of 12 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 12.
Upgrade to Pro
11 of these are in force and held by Regeneron Pharmaceuticals, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited